Evidence map›Paper›PMID 40659841›Full record

ArticleMolecular psychiatry2025

Targeting complement C3/C3aR pathway restores rejuvenation factor PF4 and mitigates neurocognitive impairments in age-related perioperative neurocognitive disorders.

Jia-Li Wang, Cai-Hong Ye, Zhong-Fa Teng, Kai Zhou, Li-Li Pan, Man-Duo Ouyan, Zhi Zheng, Meng Lu, Shi-Lei Li, Jing Zhang and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jia-Li Wang *Department of Anesthesiology, Fujian Medical University Union Hospital, 29 Xin-Quan Road, Fuzhou, Fujian, 350001, China.ORCID http://orcid.org/0009-0004-0632-8629
Cai-Hong Ye *Department of Anesthesiology, Fujian Medical University Union Hospital, 29 Xin-Quan Road, Fuzhou, Fujian, 350001, China.
Zhong-Fa TengDepartment of Anesthesiology, Fujian Medical University Union Hospital, 29 Xin-Quan Road, Fuzhou, Fujian, 350001, China.
Kai ZhouDepartment of Urology, Fujian Medical University Union hospital, 29 Xin-Quan Road, Fuzhou, Fujian, 350001, China.
Li-Li PanFujian Institute of Hematology, 29 Xin-Quan Road, Fuzhou, Fujian, 350001, China.
Man-Duo OuyanDepartment of Emergency Surgery, Fujian Medical University Union Hospital, 29 Xin-Quan Road, Fuzhou, Fujian, 350001, China.
Zhi ZhengDepartment of Oral Surgery, Fujian Medical University Union Hospital, 29 Xin-Quan Road, Fuzhou, Fujian, 350001, China.
Meng LuDepartment of Oral Surgery, Fujian Medical University Union Hospital, 29 Xin-Quan Road, Fuzhou, Fujian, 350001, China.
Shi-Lei LiDepartment of Anesthesiology, Fujian Medical University Union Hospital, 29 Xin-Quan Road, Fuzhou, Fujian, 350001, China.
Jing ZhangCenter for Advanced Vision Science, University of Virginia, Charlottesville, VA, USA.
Pei-Chan ZhengFujian Center for Safety Evaluation of New Drug, Fujian Medical University, Fuzhou, Fujian, China.
Jingjing ZhangCenter for Advanced Vision Science, University of Virginia, Charlottesville, VA, USA.
Hui ZhangFujian Key Laboratory of Natural Medicine Pharmacology, School of Pharmacy, Fujian Medical University, Fuzhou, China.
Mei-Hong LinDepartment of Anesthesiology, Fujian Medical University Union Hospital, 29 Xin-Quan Road, Fuzhou, Fujian, 350001, China.
Liang-Cheng ZhangDepartment of Anesthesiology, Fujian Medical University Union Hospital, 29 Xin-Quan Road, Fuzhou, Fujian, 350001, China.
Shi-Shi HuangDepartment of Anesthesiology, Fujian Medical University Union Hospital, 29 Xin-Quan Road, Fuzhou, Fujian, 350001, China.
Xiao-Ning RenDepartment of Anesthesiology, Fujian Medical University Union Hospital, 29 Xin-Quan Road, Fuzhou, Fujian, 350001, China.
Ning ZhengDepartment of Anesthesiology, Fujian Medical University Union Hospital, 29 Xin-Quan Road, Fuzhou, Fujian, 350001, China.
Wen-Lin WeiDepartment of Anesthesiology, Fujian Medical University Union Hospital, 29 Xin-Quan Road, Fuzhou, Fujian, 350001, China.
Zhenhuan ZhaoCenter for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, 430068, China. zhaozhenhuan@hbut.edu.cn.
Shao-Bin WangCenter for Advanced Vision Science, University of Virginia, Charlottesville, VA, USA. sw3ta@virginia.edu.
Zhong-Meng LaiDepartment of Anesthesiology, Fujian Medical University Union Hospital, 29 Xin-Quan Road, Fuzhou, Fujian, 350001, China. zl7mg@fjmu.edu.cn.ORCID http://orcid.org/0000-0002-3429-1489

Funding

Hubei University of Technology (HBUT) GCC2024015
6 · The paper itself

Abstract

Perioperative neurocognitive disorders (PND), including postoperative delirium (POD), delayed neurocognitive recovery (dNCR) and postoperative neurocognitive disorder (PNCD), affect up to 10% of surgical patients older than 60 years, and currently there are no effective therapies to prevent PND. The gut microbiota is linked to PND through the gut-brain axis, promoting neuroinflammation via activation and proliferation of microglia and astrocytes in the central nervous system (CNS). In this study, we show that perioperative use of ceftriaxone, a long-acting β-lactam antibiotic, can prevent the development of PND in elderly surgical patients. This effect is associated with reduced serum complement C3 levels and increased levels of platelet factor 4 (PF4). Using an aged mouse model of PND, we found that C3/C3aR axis mediated the interaction of astroglia and microglia during the early stages of neuroinflammation. Genetic ablation or pharmacological blockade of C3/C3aR signaling pathway suppressed neuroinflammation and attenuated cognitive declines in PND. The C3/C3aR axis is essential for surgery-induced platelet count and circulating PF4 declines, and mice supplemented with recombinant PF4 exhibited reduced neuroinflammation and improved cognitive function. Together, our findings revealed the new roles of the C3/C3aR signaling pathway in platelet dysfunction and neuroinflammation in age-related PND, and these results highlight new potential therapeutic strategies for PND.

Indexed as

Complement C3Neurocognitive DisordersPlatelet Factor 4Receptors, ComplementAgedAgingAnimalsAstrocytesBrainCeftriaxoneDisease Models, AnimalFemaleHumansMaleMiceMice, Inbred C57BLCeftriaxoneComplement C3complement C3a receptorPlatelet Factor 4Receptors, Complement

Identifiers

PMID40659841

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.